Clinical trials: Dopamine
Parkinson Disease
Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment
This study will evaluate the efficacy and safety of AKST4290 in subjects with Parkinson's Disease who are currently on stable dopaminergic treatment.
- Trial name
- TEAL (NCT04369430)
- Testing
- AKST4290
- Where
- 22 sites in United States, Estonia and 3 more
- Volunteers
- 110 people
- Sponsor
- Alkahest, Inc.
Major Depression
Lexapro and Pramipexole and to Treat Major Depression
This study compares the effectiveness of the combination of antidepressants: Lexapro and Pramipexole, with the effectiveness of each antidepressant alone.
- Trial name
- NCT00086307
- Testing
- Pramipexole, Escitalopram
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder, Dysthymia
L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults
Individuals with Late Life Depression (LLD) often have cognitive problems, particularly problems with memory, attention, and problem solving, all of which contribute to antidepressant non-response.
- Conditions
- Major Depressive Disorder, Dysthymia, Depression
- Trial name
- NCT03761030
- Testing
- L-DOPA
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- New York State Psychiatric Institute
Parkinson's Disease
Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists
The purpose of the study is to determine if reducing or eliminating a dopamine agonist (DA) causing one of the side effects of daytime sleepiness, swelling of the lower legs or feet, hallucinations or impulsive behaviors while…
- Trial name
- AtoZ (NCT00443872)
- Testing
- orally disintegrating selegiline (Zelapar)
- Where
- 17 sites in United States
- Volunteers
- 77 people
- Sponsor
- Parkinson's Disease and Movement Disorder Center of Boca Raton
Bipolar Disorder, Pediatric
Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)
Efficacy and safety of asenapine for the treatment of bipolar I disorder (manic or mixed episodes) will be evaluated in participants between 10 and 17 years old, who are either hospitalized or non-hospitalized.
- Trial name
- NCT01244815
- Testing
- asenapine, Rescue medication
- Volunteers
- 404 people
- Sponsor
- Organon and Co
Schizophrenia
A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with receiving multiple drugs schizophrenia.
- Trial name
- NCT01626885
- Testing
- MP-214
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Tanabe Pharma Corporation
Lewy Body Dementia
A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
A randomized placebo-controlled trial to evaluate the safety and efficacy of three doses of study drug LY3154207 treated for 12 weeks in participants with mild-to-moderate dementia associated with LBD (PDD or DLB).
- Trial name
- PRESENCE (NCT03305809)
- Testing
- LY3154207
- Where
- 77 sites in United States, Canada and 1 more
- Volunteers
- 344 people
- Sponsor
- Eli Lilly and Company
Posttraumatic Stress Disorder
Nepicastat for Posttraumatic Stress Disorder (PTSD) in OIF/OEF Veterans
This study proposes a multi-site, randomized, double-blind, placebo-controlled clinical trial of the dopamine-ß-hydroxylase (DBH) inhibitor, nepicastat, for the treatment of posttraumatic stress disorder (PTSD) in outpatients who…
- Trial name
- Nepicastat (NCT00659230)
- Testing
- Nepicastat
- Where
- 3 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Tuscaloosa Research & Education Advancement Corporation
Alcohol Use Disorder
Effects of Cortical Dopamine Regulation on Drinking, Craving, and Cognitive Control
The purpose of this study is to determine whether the catechol-O-methyltransferase (COMT) inhibitor tolcapone, relative to placebo, reduces alcohol drinking and alcohol cue-elicited brain activation and increases brain activation…
- Trial name
- NCT02949934
- Testing
- Tolcapone
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Medical University of South Carolina
Schizophrenia
Safety and Efficacy of Cariprazine in Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.
- Trial name
- NCT01104779
- Testing
- Cariprazine
- Where
- 41 sites in United States, Colombia and 2 more
- Volunteers
- 446 people
- Sponsor
- Forest Laboratories
Anorexia Nervosa
Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa
Anorexia nervosa (AN) is an eating disorder associated with intense fear of weight gain, food refusal, and severe weight loss. AN has the highest mortality rate among the psychiatric disorders; however, little is known about…
- Trial name
- NCT04128683
- Testing
- amisulpride, bromocriptine
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Schizophrenia
Clinical Trial of Tolcapone for Cognition in Schizophrenia
This study will evaluate whether Tolcapone improves cognition in healthy volunteers as well as patients with schizophrenia. Talcapone is a drug that has been FDA approved for Attention Deficit Disorder and allegedly increase the…
- Trial name
- NCT00044083
- Testing
- Tolcapone
- Where
- United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Cognition Disorder, Attention Deficit Disorder
Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI
Deficits in memory, attention, cognitive, and executive functions are the most common disabilities after traumatic brain injury (TBI).
- Conditions
- Cognition Disorder, Attention Deficit Disorder, Traumatic Brain Injury
- Trial name
- DAPET-TBI (NCT02225106)
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Pennsylvania
Parkinson Disease
Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole
Subjects stable on L-Dopa and oral ropinirole will have their ropinirole replaced with the Ropinirole Implant(s). The Ropinirole Implant was designed using the ProNeura™ implant technology where the implant is inserted under the…
- Trial name
- NCT03250117
- Testing
- Ropinirole oral product, Ropinirole Implant
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Titan Pharmaceuticals
Parkinsonian Signs in Older Persons
Neurobiological Drivers of Mobility Resilience: The Dopaminergic System
Walking with age becomes both slower and less 'automated', requiring more attention and brain resources. As a result, older adults have a greater risk of negative outcomes and falls.
- Trial name
- RES (NCT04325503)
- Testing
- carbidopa
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Michigan
Schizophrenia
Safety and Efficacy of Cariprazine in Patients With Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.
- Trial name
- NCT01104766
- Testing
- Cariprazine, Aripiprazole
- Where
- 58 sites in United States, Romania and 2 more
- Volunteers
- 617 people
- Sponsor
- Forest Laboratories
Opiod Use Disorder
The Influence of ANS-6637 on Midazolam Pharmacokinetics in Healthy Volunteers
Background: Opioids are medicines that control pain. But they are often misused, which can lead to illness and death. Opioids increase dopamine to the brain, which makes people feel good and often causes them to crave drugs…
- Trial name
- NCT03831971
- Testing
- ANS-6637
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Parkinson's Disease
Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch
The purpose of this study is to show Rotigotine dose response at four doses of Rotigotine used with L-dopa in treating advanced stage Parkinson's disease.
- Trial name
- NCT00522379
- Testing
- Rotigotine
- Where
- 77 sites in United States, Chile and 3 more
- Volunteers
- 514 people
- Sponsor
- UCB Pharma
Schizophrenia
Oculomotor and Spatial Cognition Deficits in Schizophrenia
DESCRIPTION: (Verbatim from the Applicant's Abstract) Abnormalities of eye movement control and spatial cognition are well-established deficits in schizophrenia.
- Trial name
- NCT00931996
- Testing
- Antipsychotic
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Schizophrenia
Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity
Schizophrenia is a devastating and complex illness, with multiple symptom and behavioral manifestations. Antipsychotic medications are the mainstay of treatment; however, many patients only partially respond to treatment.
- Trial name
- NCT02118610
- Testing
- L-tetrahydropalmatine (30mg), Sugar pill
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of Maryland, Baltimore